Retrieved May 2, 2025, from (Content notes FDA approval 1997 and withdrawal 2008 for commercial reasons.) Askinazi, O
CagriSema is a new medicine that combines Cagrilintide and Semaglutide and is not yet available from doctors
If you are noticing breath changes, add a modest 1530 gram slow carb source once daily for 2472 hours, think a small sweet potato or a cup of berries with yogurt, and monitor whether breath improves the following morning
Summary: Retatrutide is administered as a once-weekly subcutaneous injection under strict clinical trial supervision, as it has not yet received MHRA or EMA approval for routine use in the UK
Separation Science Plus
Other trials will examine the effect of retatrutide on obstructive sleep apnea, chronic kidney disease, type 2 diabetes, major adverse cardiac events, and low back pain in addition to weight loss with expected readouts in 2026 and 2027